The Patent Finder

Jeil Pharmaceutical Co., Ltd.

Also on record
Records under this name other than the patents Jeil Pharmaceutical Co., Ltd. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 4 patents it holds.

Showing 1 to 9 of 9 · Back to Jeil Pharmaceutical Co., Ltd.

Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleStatus Expires Confidence
US 10,260,049Attenuated Reovirus
Formerly held
In force
 · High confidence
In forceHigh confidence
US 8,492,149Efficient generation of neural progenitors, neurons, and dopaminergic neurons from human embryonic stem cells
Formerly held
In force
 · USPTO record
In forceUSPTO record
US 10,369,171Attenuated reoviruses for selection of cell populations
Formerly held
In force
 · USPTO record
In forceUSPTO record
US 8,906,395Pharmaceutical composition in which solubility of partially soluble tricyclic derivative is improved
Formerly held
In force
 · USPTO record
In forceUSPTO record
US 10,464,919Tricyclic derivative compound, method for preparing same, and pharmaceutical composition comprising same
Formerly held
In force
 · USPTO record
In forceUSPTO record
US 11,898,164Method for producing pluripotent stem cell-derived spherical neural mass having suppressed teratoma formation
Formerly held
In force
 · USPTO record
In forceUSPTO record
US 8,742,160Method for preparing tricyclic derivatives
Formerly held
Lapsed on the fee record
Ended Jun 3, 2026 · USPTO record
Lapsed on the fee recordEnded Jun 3, 2026USPTO record
US 8,334,277{4-[2-(dimethylamino)-1-(1-hydroxycyclohexyl)ethyl]phenoxy}phosphate or a pharmaceutically acceptable salt thereof, a production method therefor and a pharmaceutical composition for preventing and treating central nervous system disorders containing the same as an active component
Lapsed on the fee record
Ended Dec 18, 2020 · USPTO record
Lapsed on the fee recordEnded Dec 18, 2020USPTO record
US 5,859,016Memory enhancing and anti-dementia agent containing dehydroevodiamine HC1 as active ingredient
Formerly held
Term ended
Term ended no later than Jan 12, 2019 · Low confidence
Term endedTerm ended no later than Jan 12, 2019Low confidence
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 20, 2026 · includes USPTO assignment data published Nov 19, 2026, status data published Nov 20, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited